Mats-Olof Wallin
Director of Finance/CFO en OxThera AB .
Perfil
Mats-Olof Wallin is currently the Chief Financial Officer & Deputy CEO at OxThera AB since 2020.
Prior to this, he worked as the CFO & Director-Investor Relations at Biotage AB from 2003 to 2012, the Chief Financial Officer at Karo Healthcare AB from 2018 to 2019, and the Chief Financial Officer & Senior Vice President at Swedish Orphan Biovitrum AB from 2013 to 2018.
He completed his undergraduate degree from the University of Uppsala.
Cargos activos de Mats-Olof Wallin
| Empresas | Cargo | Inicio |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Director of Finance/CFO | 01/01/2020 |
Antiguos cargos conocidos de Mats-Olof Wallin.
| Empresas | Cargo | Fin |
|---|---|---|
| KARO PHARMA AB (PUBL) | Director of Finance/CFO | 01/10/2019 |
| SWEDISH ORPHAN BIOVITRUM AB | Director of Finance/CFO | 20/07/2018 |
| BIOTAGE AB | Director of Finance/CFO | 01/01/2012 |
Formación de Mats-Olof Wallin.
| University of Uppsala | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| KARO PHARMA AB (PUBL) | Health Technology |
| BIOTAGE AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Mats-Olof Wallin
